盐酸司来吉兰治疗早期帕金森病的疗效观察

目的 观察司来吉兰治疗早期帕金森病（PD）的疗效和安全性。方法 采用随机空白对照法，将60例已用安坦、金刚烷胺、维生素E联合治疗的早期PD患者分为司来吉兰治疗组和空白对照组，前者在原用药物剂量不变的基础上添加盐酸司来吉兰片5mg/d，疗程8周。采用改良Webster评分评价药物疗效并观察不良反应。结果 司来吉兰组治疗后4周及8周时改良Webster评分较治疗前明显改善（均P〈0．01），且明显低于空白对照组（均P〈0．05）；司来吉兰组总有效率为76．7％，明显优于空白对照组（P〈0．01）；未见明显不良反应。结论 司来吉兰是一种安全有效的早期PD治疗用药。

Therapeutic effect observation of selegiline hydrochloride in early stage of Parkinson's disease

Objective To study the efficacy and safety of selegiline in the treatment of patients with Parkinson's disease (PD) at early stage. Methods The randomized and blank controlled study was performed. Sixty PD patients at early stage who had been treated with trihexyphenidyl, amantadine and vitaminE were divided into two groups. One was added to selegiline hydrochloride (5 mg/d) for eight weeks, the other was blank controlled group. Efficacy of selegiline in each patient was evaluated by modified Webster scale. Tolerance and adverse effects were also observed.Results After four and eight weeks, the score of modified Webster scale of selegiline group was lower than that before selegiline treatment (all (P<)0.01) and that of blank controlled group (all (P<)0.05). The total effective rate of selegiline group was 76.7%, also better than blank controlled group ((P<)0.01). The adverse effects in selegiline treatment group were mild. Conclusion It is showed that selegiline is a safe and effective drug for PD at early stage.